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BACKGROUND: Epigenetic silencing of O
6-methylguanine-DNA-methyltransferase (MGMT) by promoter methylation is associated with
improved survival in glioblastomas treated with alkylating agents. In this study, we investigated MGMT promoter methylation in
glioblastomas treated with temozolomide and radiotherapy in a single UK treatment centre.
METHODS: Quantitative methylation data at individual CpG sites were obtained by pyrosequencing for 109 glioblastomas.
RESULTS: Median overall survival (OS) was 12.4 months with 2-year survival of 17.9%. Pyrosequencing data were reproducible with
archival samples yielding data for all glioblastomas. Variation in methylation patterns of discrete CpG sites and intratumoral
methylation heterogeneity were observed. A total of 58 out of 109 glioblastomas showed average methylation 4non-neoplastic
brain in at least one clinical sample; 86% had homogeneous methylation status in multiple samples. Methylation was an independent
prognostic factor associated with prolonged progression-free survival (PFS) and OS. Cases with methylation more than 35% had the
longest survival (median PFS 19.2; OS 26.2 months, 2-year survival of 59.7%). Significant differences in PFS were seen between those
with intermediate or high methylation and unmethylated cases, whereas cases with low, intermediate or high methylation all showed
significantly different OS.
CONCLUSIONS: These data indicate that MGMT methylation is prognostically significant in glioblastomas given chemoradiotherapy in
the routine clinic; furthermore, the extent of methylation may be used to provide additional prognostic stratification.
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Glioblastoma accounts for 60–70% of gliomas, but despite
advances in therapy these tumours remain associated with poor
prognosis (Anderson et al, 2008). Until recently the mainstay of
treatment was biopsy with cytoreductive surgery where possible,
followed by radiotherapy. However, a recent phase III clinical trial
(EORTC 26981/22981 & NCIC CE.3) of concurrent temozolomide
and radiotherapy followed by adjuvant temozolomide for newly
diagnosed glioblastoma patients showed a considerable advance,
achieving a median survival of 14.6 months and 2-year survival of
26% (Stupp et al, 2005). This treatment was recommended in 2006
in the UK NICE guidelines for good performance status
glioblastoma patients, but the impact of chemoradiotherapy on
outcome in large cohorts treated in the routine clinic has not been
reported.
Alkylating chemotherapeutic agents cause DNA damage by the
transfer of alkyl groups at several sites within DNA, including
the O
6 position of guanine. The O
6-methylguanine-DNA-methyl-
transferase (MGMT) gene plays a fundamental role in maintaining
genomic integrity by encoding for a DNA repair protein that
removes alkyl groups from O
6-guanine (Hegi et al, 2008; Verbeek
et al, 2008). Epigenetic silencing by promoter methylation results
in decreased MGMT expression and correlates with improved
survival in glioma patients treated with alkylating agents (Esteller
et al, 2000; Chinot et al, 2007; Criniere et al, 2007; Eoli et al, 2007;
Hegi et al, 2008). The prognostic significance of MGMT promoter
methylation has been shown in two chemoradiotherapy clinical
trials; first in a phase II study testing concomitant and adjuvant
temozolomide and radiation (Hegi et al, 2004) and subsequently in
EORTC 26981/22981 & NCIC CE.3 (Hegi et al, 2005). In the later
study, MGMT promoter methylation was an independent favour-
able prognostic factor and patients whose tumour contained a
methylated MGMT promoter had median survival of 21.7 months
and 2-year survival of 46%, when treated with temozolomide and
radiotherapy. These studies suggest that determination of MGMT
methylation status maybe an important factor in determining
which glioblastoma patients should receive chemoradiotherapy
(Gorlia et al, 2008), but its prognostic significance in the routine
clinical setting is not clearly established.
Methylation-specific PCR (MSP) is widely used to test MGMT
promoter methylation; however, in EORTC 26981/22981 & NCIC
CE.3 Hegi et al (Hegi et al, 2005) only achieved methylation data
for 67% of samples analysed, representing 36% of cases. The MSP
assay is prone to lack of reliability attributed to poor quality
archival tissue and small sample size and optimum results are
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susually obtained with cryopreserved tissues (Hegi et al, 2005; Yip
et al, 2008). A number of improvements (Cankovic et al, 2007) and
alternative methods including semi-quantative methods have been
developed (Jeuken et al, 2007; Lorente et al, 2008; Vlassenbroeck
et al, 2008). Pyrosequencing allows highly reproducible quantifica-
tion of methylation at each CpG site within the chosen amplicon
and has been found to be robust when applied to archival samples
including glioblastomas (Mikeska et al, 2007), but use of
pyrosequencing in analysis of extensive glioblastoma cohorts and
comparison with outcome data has not been reported.
The aim of this study was to determine whether pyrosequencing
may be used to determine MGMT promoter methylation status
using archival tissue samples from glioblastomas and to investigate
the prognostic significance of MGMT promoter methylation in
patients treated in the routine clinic with concurrent temozo-
lomide and radiotherapy followed by adjuvant temozolomide.
PATIENTS AND METHODS
Case selection
The study included 109 newly diagnosed, previously untreated
glioblastomas WHO grade IV diagnosed between June 2004 and
October 2007 (Table 1). These patients had cytoreductive surgery
where possible or biopsy at the Walton Centre for Neurology and
Neurosurgery before radical treatment at Clatterbridge Center for
Oncology with radiotherapy and concurrent temozolomide
(75mgm
 2 per day) and radiotherapy followed 4 weeks later by
adjuvant temozolomide (150mgm
 2 for 5 days and increased to
200mgm
 2 for 5 days in subsequent cycles depending on blood
counts and tolerability, six cycles planned). A total of 60 and 55Gy
were prescribed to 104 and 5 patients, respectively, in 30 fractions.
In the preliminary experiments, 12 archival glioblastomas and
high-grade glioma cell lines U373, HS683, T98G and U87MG were
investigated to validate the pyrosequencing assay. Six non-
neoplastic brain samples: two whole brain DNA extracts (AMS
Bio D1234035-50, Abingdon, UK) and four temporal lobectomies
from epilepsy surgery (two formalin-fixed paraffin-embedded
(FFPE); two snap frozen) were also investigated. The study had
the ethics committee approval.
Clinical data
Clinical data were collated retrospectively for all patients treated
by chemoradiotherapy within the study period (n¼115). Response
was monitored with computed tomography or magnetic resonance
imaging scans after radiotherapy, before the fourth cycle and
after the sixth cycle. Scans were performed if there was clinical
suspicion of disease progression and at regular 6-monthly intervals
during follow-up. PFS and OS were calculated from the date of
diagnosis.
Pathology and tissues
For tumour tissues, a consultant neuropathologist reconfirmed
a diagnosis of glioblastoma WHO grade IV and selected suitable
samples for analysis by visual microscopic assessment with 470%
neoplastic cells and o50% necrosis from intraoperative cytology
smear preparations or FFPE blocks for each case. Haematoxylin
and eosin or methylene blue stained smears were used as described
earlier (Walker et al, 2001) scraping the tissue into DNA extraction
buffer. Snap frozen tissue was used where available. We aimed to
analyse more than one tissue sample for each case, preferably
selecting samples from different blocks and/or with different
fixation.
DNA extraction and bisulphite treatment
The DNA was extracted using the Dneasy Blood and Tissue kit
(Qiagen cat 69506, Crawley, UK) and quantified by spectro-
photometry using a NanoDrop (NanoDrop ND-1000, Thermofisher
Scientific, Loughborough, UK). The DNA yields for frozen, smear
and FFPE samples were 6.9±7.0mg, 3.2±4.1mg and 20.9±22.2mg,
respectively. Bisulphite modification of 1mg DNA was performed
using the EZ DNA methylation kit (Zymo, Orange, CA, USA,
D5002). Each bisulphite modification experiment included
universal methylated DNA (CpGenome Universal Methylated
DNA S7821, Millipore, Watford, UK) as positive control and
normal brain DNA as negative control.
Analysis of MGMT promoter methylation
The pyrosequencing assay was performed as described earlier
(Shaw et al, 2006). The primers used for amplification of
bisulphite-treated DNA were forward: 50-gGGATAGTTGGGAT
AGTT-30 (the first g avoids formation of hairpin loops) and
reverse: 50-biotin-ATTTGGTGAGTGTTTGGG-30 giving a 99-bp
amplicon at genomic position 131155467–131155565. The PCR
analysis was performed in duplicate in 25ml reaction volume,
containing 300pmol each forward and reverse primer, 2ml1 0  
buffer, 160mM dNTPs, 0.5U HotStar Taq polymerase (Qiagen) and
1–2ml bisulphite-treated DNA. The PCR conditions were as
follows: 951C-15min; 40 cycles of 941C-30s, 501C-45s, 721C-30s;
721C-10min (Dyad, GRI, Braintree, UK). To confirm the correct
product before pyrosequencing, 3ml of PCR products were
analysed on a 2% agarose gel, the remaining 22ml was subjected
to pyrosequencing on a PSQ96MA System (Biotage, Uppsala,
Sweden) using the primer 50-GGATATGTTGGGATAGT-30and
PyroGold reagents (Biotage). The Pyro Q-CpG software 1.0.9
(Biotage) was used to analyse data.
Pyrosequencing yields data for 12 CpG sites within the MGMT
promoter. For data analysis, the percentage methylation obtained
for each CpG was averaged across the 12 CpGs in duplicate PCR
reactions (average methylation per sample). For comparisons with
clinical data, glioblastomas were considered methylated if they had
at least one sample with average methylation X9% (Xmean±
2 s.d. for non-neoplastic brain) in more than one independent
bisulphite modification. Unmethylated cases had average methyla-
tion o9% in all samples. The average methylation per case was
Table 1 Clinical characteristics of the cohort treated with chemor-
adiotherapy with methylation data (n¼109)
Clinical series
Age
Median (range) years 55 (18–68)
Sex
Male 72
Female 37
Surgery
Biopsy (open:serial stereotactic) 26 (9:17) (24%)
Resection 83 (76%)
Performance status (WHO)
0 37 (34%)
1 54 (50%)
2 16 (15%)
3 2 (2%)
Alive:dead at study 15:94
Progression-free survival
a (months) Median 9.7 months (95% CI 8.8–10.5)
Overall survival
a (months) Median 12.4 months (95% CI 10.7–14.1)
2-Year survival (%) 17.9
aCalculated from date of diagnosis.
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scalculated by averaging the average methylation per sample for
methylated samples for that case. Methylation-specific PCR assays
were carried out as described by Hegi et al (2005).
Statistics
Statistical analysis was performed using SPSS (Chicago, IL, USA).
Unsupervised hierarchical cluster analysis was performed in Gene
Spring, using Euclidean distance and centroid linkage. Survival
data were calculated from the date of diagnosis. Kaplan–Meier
survival curves were obtained and differences in PFS or OS were
tested for statistical significance using the log-rank test. Univariate
Cox regression analysis was used to determine whether MGMT
methylation status, gender, age, extent of surgery and performance
status had prognostic significance with respect to outcome. Cox
regression multivariate analysis for factors significantly associated
with survival in univariate analysis was by forward stepwise entry
of parameters at a significance of 0.05 for entry and 0.01 for
removal. Two-tailed P-values are quoted. Methylated cases were
dichotomised using receiver operator characteristic (ROC) plots
comparing average methylation per case with the Cox regression
survival function for OS.
RESULTS
MGMT methylation analysis
The pyrosequencing assay for MGMT methylation was initially
validated in a series of dilutions of in vitro methylated:
unmethylated DNA. The reproducibility of the assay, measured
by multiple repetitions at various dilutions was calculated as 3%.
The sensitivity of the assay, defined as the maximum tolerable
dilution within the reproducibility range was 5%. The next
validation phase included cell lines of known MGMT methylation
status: U373, T98G, U87MG and HS683 showed methylation
averaged across the 12 CpGs analysed of 42, 42, 64 and 5%,
respectively, consistent with their methylation status determined
by MSP (data not given). As DNA methylation is tissue specific, we
determined the background methylation in two non-neoplastic
brain extracts, which showed average methylation of o5%. We
then investigated MGMT promoter methylation by pyrosequen-
cing in five glioblastomas with frozen tissue and seven cases each
with frozen tissue, intraoperative smears and FFPE samples
meeting the selection criteria of 470% neoplastic component
and o50% necrosis. Pyrosequencing data were obtained for all
classes of sample (Supplementary Figure 1). Six glioblastomas had
average methylation o5%, whereas the remainder had methyla-
tion levels between 9–49%. A total of 5 out of 7 cases with multiple
samples per case showed agreement in methylation between tissue
samples. Four non-neoplastic brain and 109 cases treated with
temozolomide and radiotherapy were then included in the study.
Due to the potential methylation heterogeneity, we aimed to
analyse 2–3 separate clinical samples for each case, depending on
availability of tissue meeting the selection criteria. Pyrosequencing
data were obtained for 264 out of 287 tumour samples from 121
cases, but was unobtainable for 13 out of 123 paraffin-embedded
samples and 6 out of 116 intraoperative smears. In 17 cases
diagnosed by serial stereotactic biopsy with samples o1mm
3,
pyrosequencing data were obtained for 5 out of 9 frozen biopsies
and 29 out of 31 intraoperative smears. Failures may be because of
small sample size with low DNA yield or in FFPE to poor DNA
integrity. Despite some sample failure, methylation data were
obtained for at least one sample of all clinical cases investigated.
Pyrosequencing data were reproducible, showing good correla-
tion between duplicate PCR reactions from the same bisulphite
modification and between two independent bisulphite modi-
fications of the same DNA extract (Supplementary Figure 2).
Non-neoplastic brain samples had mean average methylation of
3.2±2.89 s.d. (Supplementary Figure 3), but in order to guarantee
a high specificity we employed a conservative approach of defining
hypermethylation at X95% reference range (mean normal
brain±2 s.d.). A total of 62 out of 121 (51.2%) glioblastomas
had average methylation across all CpGs in at least one clinical
sample greater than that of non-neoplastic brain (X9%) and were
classified as methylated. Average methylation in methylated and
unmethylated cases was 29±15.5 and 2.9±2.0, respectively. In 22
out of 25 frozen glioblastoma samples, the methylation status
obtained by pyrosequencing agreed with that determined by MSP;
two were unmethylated by pyrosequencing but showed methyla-
tion by MSP and one had 20% methylation but was negative by
MSP. In glioblastomas, there was considerable variation in the
methylation of individual CpG sites within amplicons and between
cases (Supplementary Figure 4a and b), with CpG11 showing the
highest methylation and CpG7 the least. To determine whether
glioblastomas have characteristic patterns of CpG methylation,
methylation at individual CpGs was normalised to the average
methylation for that sample and unsupervised hierarchical analysis
performed, but discrete clusters were not obtained (data not
given).
MGMT methylation heterogeneity
Inter and intratumoral heterogeneity in the extent of MGMT
methylation was observed. Data were obtained for multiple tissue
samples in 93 glioblastomas; some had marked variation in
methylation between separate tissue samples, whereas others
showed close agreement (Figure 1). Where intratumoral hetero-
geneity was observed, the analysis was repeated and an additional
tissue sample was selected for analysis where available. For FFPE
and frozen tissue, the histology was reassessed to ensure that the
selection criteria had been met. No obvious morphological
differences were evident to account for MGMT methylation
heterogeneity. Eighty (86%) had the same methylation status in
all samples analysed. A total of 13 cases showed methylation 49%
in at least one, but not all clinical samples; in 11 out of 12
methylation was seen in FFPE samples with intraoperative smears
or frozen tissue samples being unmethylated; in 9 out of 13 the
methylated samples had methylation o21%. In one case with
distinct astrocytic and oligodendroglial histology both components
were methylated with 20.5 and 21.5%, respectively.
MGMT methylation and clinical outcome in glioblastomas
treated with chemoradiation
Of 115 patients treated with chemoradiation during the study
period, 15 (13%) had temozolomide stopped during radiotherapy,
due to clinical deterioration (2) or toxic effects (9) [missing data
(4)]. 83 (72%) patients received adjuvant temozolomide (median 4
cycles, range 1-6) with 41 (50%) completing 6 cycles. Adjuvant
temozolomide was stopped early due to disease progression (21),
clinical deterioration (9), death (2), toxic effects (6) or other (4).
Four patients had histology elsewhere and two with inadequate
tissue were not included. Methylation data were obtained for 109
cases of which 58 (53.2%) were methylated. Median OS for the
complete cohort of 115 patients was 12.8 months, comparing well
with the subset with methylation data (Table 1). There was no
association between MGMT methylation and gender, age, biopsy vs
resection or tumour location. The MGMT promoter methylation
was highly significantly associated with prolonged PFS and OS
(Figure 2A and B; Table 2). Surgery, but not age or performance
status influenced outcome. Resected cases had prolonged OS but
not PFS compared to those with biopsy only (Log-rank PFS:
P¼0.312; OS: P¼0.0002). The MGMT status was an independent
prognostic variable for both PFS and OS (Cox Regression hazard
ratio (methylated cases relative to unmethylated cases): PFS - 0.37
MGMT promoter methylation in glioblastomas
J Dunn et al
126
British Journal of Cancer (2009) 101(1), 124–131 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(95% CI 0.23-0.61), P¼0.0001; OS - 0.25 (95% CI 0.15-0.40),
P¼0.0000).
Extent of methylation and clinical outcome
In order to determine whether the extent of methylation may be
used to provide further prognostic stratification, the average
methylation per case was compared with clinical outcome. When
methylated cases were ranked according to methylation and
divided into three groups, all groups had a longer OS than did the
unmethylated cases, and those with the highest methylation
(435%) showed the longest PFS and OS (median 26.2 months)
with a 2-year survival of 59.7% (Figure 2C and D, Table 2),
suggesting that the extent of methylation impacts on survival.
Receiver operator characteristic analysis used to separate methyl-
ated cases into two prognostic groups yielded a cut-off of 29.4%
with 71.4% sensitivity and 63% specificity (ROC area 0.759
P¼0.001). Kaplan–Meier plots for PFS and OS using this cut-off
are shown in Figure 2E and F. Log-rank tests showed highly
significant differences in OS between unmethylated and both
methylated groups and between cases with low vs high methyl-
ation. The 2-year survival of the highly methylated group was
56.7% with median OS at 26.2 months (Table 2). Progression-free
survival was highly significantly different between low and high
methylated groups and between highly methylated and unmethy-
lated cases. In the analysis above, the percentage methylation was
averaged between methylated tissue samples when methylation
data were available for more than one clinical sample per case.
Similar Kaplan–Meier plots were obtained and conclusions
supported when the percentage methylation for the sample with
the highest methylation for each case was used for comparison
with outcome data (data not given). As methylation varied across
CpG sites and between cases, unsupervised hierarchical cluster
analysis was performed to identify groups of tumours with similar
methylation for comparison with outcome data (Supplementary
Figure 4b and c). Three main clusters were identified: cluster 1
corresponded to tumours classified as unmethylated; cluster 2 had
cases with lower levels of methylation; cluster 3 had cases with high
methylation seen in the majority of CpG sites. Survival curves were
similar to that seen for groups in Figure 2E and F, but the highest
methylated cluster had a median survival of 23.8 months and a
2-year survival of 49.5%.
DISCUSSION
Although numerous studies have reported associations between
MGMT and survival in glioblastomas treated with alkylating
agents, few reports support the findings of EORTC 26981/22981 &
NCIC CE.3 in large cohorts treated with temozolomide and
radiotherapy (Hegi et al, 2005; Stupp et al, 2005; Brandes et al,
2008). Given the importance to the clinical management of
glioblastoma patients, experience in the routine clinic is essential
for these advances to have full clinical benefit. Our cohort
represents consecutive patients treated in a single centre over a
40-month period except six patients and comparison of survival
data supports little selection bias in the study. The cohort with
methylation data had similar median age and range, performance
status and proportion of patients with biopsy vs debulking surgery
compared with Stupp et al (2005). Progression-free survival was
9.7 months compared with 6.9 months reported by Stupp et al
(Stupp et al, 2005), which may reflect response evaluation and
follow-up achieved in routine practice. Overall survival was 12.4
months in contrast to 14.6 months, but this is not an unexpected
finding as outcome in clinical trials is often somewhat better than
that obtained in a routine clinical environment.
MGMT levels in tumours have been measured by the assessment
of protein and gene expression, analysis of enzyme activity or
investigation of epigenetic silencing through promoter methyla-
tion. However, most studies report poor agreement between these
methods (Brell et al, 2005; Maxwell et al, 2006; Preusser et al, 2008;
Rodriguez et al, 2008; Sasai et al, 2008; Yachi et al, 2008) and most
correlations with outcome have been obtained through investiga-
tion of promoter methylation (Hegi et al, 2008; Preusser et al,
2008). Unlike the MSP assay used in the majority of clinical
studies, pyrosequencing allows highly reproducible quantitative
evaluation of methylation at discrete CpG sites thereby providing
more information on promoter methylation status and facilitating
analysis of specific methylation patterns. Analysis is fast and
cost effective and, unlike conventional bisulphite sequencing
(Grasbon-Frodl et al, 2007; Mikeska et al, 2007; Parkinson et al,
2008), is practical in a diagnostic environment. In our assay, the
PCR primers are methylation independent and as little as 5%
methylated DNA in a mixture of methylated and unmethylated
DNA may be detected. Furthermore, the assay contains an internal
control to verify successful bisulphite treatment of the starting
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Figure 1 Intratumoral methylation heterogeneity seen in cases with analysis of multiple samples per case. All samples in cases 1–46 had methylation
o9% and were classified unmethylated; whereas cases 47–93 showed methylation X9% in at least one tissue sample per case and were considered
methylated. m snap frozen tumour tissue; v FFPE samples; ’ intraoperative cytology smear preparations. The reference line at 9% is the cut-off used to
distinguish methylated from unmethylated cases.
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sTable 2 MGMT promoter methylation and outcome
Progression-free survival
a
Overall survival
a
Median (95% CI) (months) Median (95% CI) (months) 2-year survival (%)
yUnmethylated (n¼51) 8.3 (5.1–11.5) 11.1 (8.8–13.3) 0
Methylated (X9% methylation) (n¼58) 11.8 (9.9–13.6) 16.8 (13.2–20.4) 35.2
#Methylated (49t op20% methylation) (n¼20) 7.5 (6.3–8.7) 11.3 (6.2–16.3) 13.3
Methylated (420 to p35% methylation) (n¼19) 11.8 (8.9–14.6) 15.5 (12.9–18.2) 34.2
Methylated (435% methylation) (n¼19) 19.2 (11.9–26.5) 26.2 (23.0–29.5) 59.7
$Methylated (49t oo29% methylation) (n¼33) 9.5 (8.6–10.4) 14.6 (12.0–17.2) 18.4
Methylated (429% methylation) (n¼25) 18.8 (15.5–22.2) 26.2 (22.9–29.6) 56.7
aCalculated from date of diagnosis. Kaplan–Meier plots in Figure 2
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Progression-free survival (days) Overall survival (days)
P=0.0000
0 365 730 1095 1460
0 365 730 1095 1460
0 365 730 1095 1460
P=0.0000
1 vs 2   0.9998
1 vs 3   0.0007
1 vs 4   0.0000
2 vs 3   0.0107
2 vs 4   0.0001
3 vs 4   0.0597
Log-rank P
1 vs 2   0.0247
1 vs 3   0.0002
1 vs 4   0.0000
2 vs 3   0.1017
2 vs 4   0.0003
3 vs 4   0.0820
Log-rank P
1 vs 2   0.0714
1 vs 3   0.0000
2 vs 3   0.0025
Log-rank P
1 vs 2   0.0006
1 vs 3   0.0000
2 vs 3   0.0019
Log-rank P
1 Unmethylated ≤9%
(n=51)
Methylated >9 to ≤ 20%
(n=20)
2
Methylated >20 to ≤ 35%
(n=19)
3
Methylated >35%
(n=19)
4
Unmethylated ≤9%
(n=51)
1 Unmethylated ≤9%
(n=51)
Methylated >9 to ≤ 29%
(n=33)
2
Methylated >29%
(n=25)
3
Methylated >9%
(n=58)
Figure 2 Comparison of MGMT methylation with (A, C and E) progression-free survival and (B, D and F) overall survival. In (A and B) methylated cases
are compared with unmethylated cases. In (C and D) methylated cases were ordered according to degree of methylation and divided into three groups.
In (E and F) methylated cases were divided into two groups according to a cut-off determined by ROC analysis.
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sDNA. In our study, the criteria for sample selection of 470%
neoplastic cells and of o50% necrosis was met through analysis of
small samples after macrodissection where necessary or use of
serial stereotactic biopsies. Pyrosequencing was successfully used
to analyse frozen, paraffin-embedded formalin-fixed and ethanol
fixed (intraoperative smear) tissue from our diagnostic archives,
including samples of o1mm
3 from serial stereotactic biopsies.
Data were obtained for at least one sample for all glioblastomas in
the clinical series.
The various qualitative and quantitative methods for the
analysis of MGMT promoter methylation in clinical samples have
been reviewed recently (Yip et al, 2008; Preusser, 2009). Mikeska
et al (Mikeska et al, 2007) used a similar pyrosequencing assay but
MGMT methylation was analysed at only four CpG sites (CpG 9,
10, 11 and 12 in our assay). They also tested COBRA (combined
bisulphite restriction analysis) and SIRPH (SNuPE ion pair-reverse
phase high-performance liquid chromatography), but found
pyrosequencing the most sensitive, robust and easy to use. The
region of the MGMT promoter sequenced in our assay overlaps
with that analysed in the MSP assay used by Hegi et al (2005),
which relies on annealing of primers across nine CpG sites of
which the five CpGs in the forward primer correspond to CpGs
5–9 in our assay. Agreement in methylation status between MSP
and pyrosequencing was obtained in 88% frozen glioblastoma
samples and 100% cell lines tested. Methylation seen in MSP but
not in pyrosequencing may be because of the increased sensitivity
of MSP detecting methylation in minor populations of tumour cells
or false positives, whereas methylation obtained by pyrosequen-
cing and not MSP may reflect the primer positions. More recently a
quantitative real-time MSP assay, in which the copy number of
methylated MGMT alleles is calculated, improved upon the gel-
based MSP assay in terms of reproducibility and use with archival
samples, but does not provide methylation data at individual CpG
sites (Vlassenbroeck et al, 2008).
The MSP assay yields binary data without a quantitative
measure of the contribution from unmethylated DNA, which
arises from non-neoplastic cells within the tissue or from tumour
cells lacking MGMT methylation. Consequently, tumours with
high proportions of methylated tumour cells will score the same in
the MSP assay as tumours bearing only a few methylated cells, thus
underestimating methylation heterogeneity. Pyrosequencing pro-
vides quantitative data for the proportions of methylated vs
unmethylated cytosines at each CpG assayed. As in other studies,
we observed heterogeneity in methylation of discrete CpG sites
within the amplicon and between different cases (Mikeska et al,
2007; Yachi et al, 2008). Although multiple samples from the same
case showed similar patterns of methylation across the 12 CpGs
analysed, many cases showed some variation in the extent of their
methylation, indicating a degree of intratumoral methylation
heterogeneity in many glioblastomas in our series. As tumour
samples were chosen to have 470% neoplastic cells, these data
suggest variation in the numbers of methylated tumour cells in
different regions of glioblastoma tissues. Similarly, glioblastomas
show heterogeneous patterns of MGMT protein expression often
with regions within the same tumour displaying widely different
staining patterns (Juillerat-Jeanneret et al, 2008; Sasai et al, 2008).
On the basis of the MSP assay and bisulphite sequencing some
studies have claimed homogeneity in MGMT status within
glioblastomas (Grasbon-Frodl et al, 2007), whereas others have
reported a degree of intratumoral heterogeneity (Juillerat-Jeanner-
et et al, 2008; Parkinson et al, 2008). For example, Parkinson et al
(Parkinson et al, 2008)observed heterogeneity in MGMT promoter
methylation in 2 out of 7 glioblastomas sampling from different
regions of large glioblastomas and Juillerat-Jeanneret observed
heterogeneity in samples taken at least 3mm apart.
Comparison with clinical outcome was performed in a
number of ways. As there was no evidence of discrete methylation
patterns across individual CpGs, in the initial analysis cases were
considered methylated if methylation averaged across all 12 CpGs
in at least one sample was greater than that of non-neoplastic
brain. In support of data from EORTC 26981/22981 & NCIC CE.3
and other series treated with temozolomide and radiotherapy
(Friedman et al, 1998; Hegi et al, 2005; Brandes et al, 2008), in this
cohort methylated cases had prolonged PFS and OS and MGMT
status was an independent prognostic factor. However, median OS
was 16.8 months with 2-year survival of 35.2%, compared with 21.7
months and 46% in EORTC 26981/22981 & NCIC CE.3 and 43.6
months in the study reported by Brandes et al (Brandes et al,
2008). These differences may be related to differences in MGMT
analysis and sensitivity of the assays. Proportions of MGMT
positive cases were 53.2, 45 and 35% in this study and studies
reported by Hegi et al (Hegi et al, 2005)and Brandes et al (Brandes
et al, 2008), respectively. Alternatively, the shorter survival in our
study may reflect the routine clinical environment where all
patients with appropriate performance status were treated with
temozolomide and radiotherapy. Further prognostic stratification
was achieved when the extent of methylation (averaged across
CpG sites per sample and across methylated samples per case) was
considered. This was most readily showed when methylated cases
were split into three groups according to extent of methylation.
Cases with the greatest methylation had the longest survival.
Significant differences in PFS were seen between those with
intermediate or high methylation and unmethylated cases, whereas
cases with low, intermediate or high methylation all had
significantly different OS. Thus, the extent of methylation within
the tumour impacts on associations with survival. This may be a
reflection of the proportions of cells with silenced MGMT, but the
relationship between methylation and expression of active enzyme
has been questioned (Maxwell et al, 2006; Sasai et al, 2008).
Alternatively, high numbers of methylated cells may be a marker of
less aggressive biology, possibly in association with methylation of
other gene promoters (Iafrate and Louis, 2008). Discrimination of
methylated cases into two prognostic groups further illustrated
this effect. By either method, the group with the highest
methylation had median OS at 26.2 months and 2-year survival
of 57–60%. In order to take methylation at individual CpG sites
into account, unsupervised hierarchical cluster analysis was
performed. Unmethylated cases formed one cluster and methy-
lated tumours were divided into two clusters, all of which had
significantly different PFS and OS, further supporting the
association between extent of methylation and outcome. To our
knowledge, this is the first study to associate the extent of MGMT
promoter methylation with outcome.
In our study, a cut-off of 9% discriminated outcome between
methylated and unmethylated tumours, and a cut-off of 29% could
be used to dichotomise methylated cases into two prognostic
groups; for clinical use these values require validation in larger
series. Although consideration of the extent of methylation allows
greater prognostic stratification, a single cut-off in methylation
derived from a quantitative assay may be more useful in the clinic.
Wiewrodt et al (Wiewrodt et al, 2008) showed that patients
expressing p30fmolmg
 1 MGMT protein in the pre-treatment
tumour volume had a significantly better response to alkylating
therapy than those with MGMT protein above this level. Others
have shown that patients with low MGMT protein expression had
significantly improved survival compared with those with high
expression (Brell et al, 2005; Chinot et al, 2007; Nagane et al, 2007).
Vlassenbroeck et al (Vlassenbroeck et al, 2008) used a real-time
MSP assay to determine a clinically relevant cut-off for stratifica-
tion of glioblastomas into two distinct populations, with prog-
nostic significance in recurrent anaplastic astrocytoma but not
glioblastomas treated with temozolomide (Sadones et al, 2009).
In this study, we show that analysis of MGMT promoter
methylation by pyrosequencing is robust and reliable when used
with diagnostic samples and may be used to distinguish two or
more prognostic groups in response to chemoradiotherapy. The
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the necessity for careful selection of representative tissue before
assay and for analysis of more than one tissue sample per case to
exclude false negatives. In our study serial stereotactic biopsy,
which delivers multiple samples from a trajectory calculated to
traverse the most aggressive parts of the tumour based on MR
imaging, and intraoperative diagnosis for both biopsies and
resected cases ensured that solid tumour tissue rather than infil-
trative edge was available for diagnosis. Where surgical practice
differs, samples for analysis with 470% neoplastic cells may be
difficult to achieve, but the assay sensitivity would enable detection
of methylation in samples with lower tumour content. These data
support the potential use of the MGMT pyrosequencing assay for
diagnostic purposes, but further inter-laboratory investigation of
the criteria for sample selection, extent of heterogeneity and
clinically relevant cut-offs in larger series would be essential.
In summary, in this study we have reported outcome data for
consecutive glioblastomas patients treated with temozolomide and
radiotherapy in a routine UK clinic and have shown that
pyrosequencing is a robust and reliable assay for the determina-
tion of MGMT promoter methylation using diagnostic archival
samples. Patients with methylated tumours had prolonged
progression-free and overall survival and the extent of methylation
could be used to achieve further prognostic stratification.
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